The hormone connection almost no one is talking about, and the data that changes everything for women in midlife Dr. Kristi Sawicki Jun 09, 2026 There’s a conversation happening in functional medicine circles that hasn’t fully made it into mainstream prescribing offices yet. It goes something like this: if you’re a perimenopausal or postmenopausal woman taking a GLP-1 receptor agonist, semaglutide or tirzepatide, and you’re not seeing the results you expected, your estrogen status may be the...

GHK-Cu is one of the most studied (and sometimes misunderstood) compounds in longevity research today.

GLP-1 medications entered the mainstream conversation through weight loss. But in academic medicine, GLP-1 signaling has been studied for years in the context of cardiovascular disease, kidney disease, fatty liver disease, and increasingly, neurodegeneration. Now a new question is emerging in longevity circles: What happens if we use very small doses—not for weight loss—but to support metabolic health as we age? This article isn’t about hype. It’s about biology, data, and careful...